title: Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat.
abstract: An orally active, nonpeptide Arg-Gly-Asp (RGD) mimetic alpha(v)beta3 antagonist, (S)-3-Oxo-8-[2-[6-(methylamino)-pyridin-2-yl]-1-ethoxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid (compound 1), has been generated, which prevented net bone loss and inhibited cancellous bone turnover in vivo. The compound binds alpha(v)beta3 and the closely related integrin alpha(v)beta5 with low nanomolar affinity but binds only weakly to the related integrins alpha(IIb)beta3, and alpha5beta1. Compound 1 inhibited alpha(v)beta3-mediated cell adhesion with an IC50 = 3 nM. More importantly, the compound inhibited human osteoclast-mediated bone resorption in vitro with an IC50 = 11 nM. In vivo, compound 1 inhibited bone resorption in a dose-dependent fashion, in the acute thyroparathyroidectomized (TPTX) rat model of bone resorption with a circulating EC50 approximately 20 microM. When dosed orally at 30 mg/kg twice a day (b.i.d.) in the chronic ovariectomy (OVX)-induced rat model of osteopenia, compound 1 also prevented bone loss. At doses ranging from 3 to 30 mg/kg b.i.d., compound 1 partially prevented the OVX-induced increase in urinary deoxypyridinoline. In addition, the compound prevented the OVX-induced reduction in cancellous bone volume (BV), trabecular number (Tb.N), and trabecular thickness (Tb.Th), as assessed by quantitative microcomputerized tomography (microCT) and static histomorphometry. Furthermore, both the 10-mg/kg and 30-mg/kg doses of compound prevented the OVX-induced increase in bone turnover, as measured by percent osteoid perimeter (%O.Pm). Together, these data indicate that the alpha(v)beta3 antagonist compound 1 inhibits OVX-induced bone loss. Mechanistically, compound 1 prevents bone loss in vivo by inhibiting osteoclast-mediated bone resorption, ultimately preventing cancellous bone turnover.
authors.affiliation: Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA.
authors.forename: M W
authors.initials: MW
authors.lastname: Lark
authors.forename: G B
authors.initials: GB
authors.lastname: Stroup
authors.forename: R A
authors.initials: RA
authors.lastname: Dodds
authors.forename: R
authors.initials: R
authors.lastname: Kapadia
authors.forename: S J
authors.initials: SJ
authors.lastname: Hoffman
authors.forename: S M
authors.initials: SM
authors.lastname: Hwang
authors.forename: I E
authors.initials: IE
authors.lastname: James
authors.forename: B
authors.initials: B
authors.lastname: Lechowska
authors.forename: X
authors.initials: X
authors.lastname: Liang
authors.forename: D J
authors.initials: DJ
authors.lastname: Rieman
authors.forename: K L
authors.initials: KL
authors.lastname: Salyers
authors.forename: K
authors.initials: K
authors.lastname: Ward
authors.forename: B R
authors.initials: BR
authors.lastname: Smith
authors.forename: W H
authors.initials: WH
authors.lastname: Miller
authors.forename: W F
authors.initials: WF
authors.lastname: Huffman
authors.forename: M
authors.initials: M
authors.lastname: Gowen
mesh_terms: D000818:Animals; D001862:Bone Resorption / Q000517:prevention & control*; D005260:Female; D010010:Osteoclasts / Q000187:drug effects* / Q000378:metabolism; D010052:Ovariectomy; D011725:Pyridines / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors*
chemical_list: D011725:Pyridines; D019030:Receptors, Vitronectin; C412426:SC 56631